Press Releases

Year:

Notify me when new press releases are posted to this site .

2/20/2012	Cubist Pharmaceuticals to Present at February/March Investor Conferences
2/16/2012	Cubist Pharmaceuticals Appoints Alison Lawton to Board of Directors
2/09/2012	Cubist Receives CUBICIN Paragraph IV Notice Letter
1/19/2012	Cubist Pharmaceuticals Reports 2011 Fourth Quarter and Full Year Financial Results
1/10/2012	Cubist Pharmaceuticals and Hydra Biosciences Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain
1/09/2012	Cubist Announces Full Year 2011 Total CUBICIN Net Product Revenues of $735.5 Million, Up 18% Over 2010
1/04/2012	Cubist Pharmaceuticals and The New England Patriots Radio Network Honor Merrimack, New Hampshire, Science Teacher
12/13/2011	Cubist Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Intra-Abdominal Infections
12/12/2011	Cubist Pharmaceuticals Completes Acquisition of Adolor Corporation
12/07/2011	Cubist Pharmaceuticals Announces Results of Initial Tender Offer for Outstanding Shares of Adolor Corporation and Commencement of Subsequent Offering Period
11/29/2011	Cubist Pharmaceuticals to Present at December 2011 Investor Conferences
11/15/2011	Cubist Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Adolor
11/07/2011	Cubist Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Adolor
10/31/2011	Cubist Pharmaceuticals to Present at November 2011 Investor Conferences
10/24/2011	Cubist Pharmaceuticals to Acquire Adolor
10/20/2011	Cubist to Feature Antibiotic Development Programs at 49th IDSA
10/19/2011	Cubist Pharmaceuticals Total Net Revenues Top $200 Million for Third Quarter 2011
10/17/2011	Cubist Pharmaceuticals Appoints Jennifer Jackson as Senior Vice President, Regulatory Affairs
10/12/2011	Cubist Pharmaceuticals to Announce Third Quarter 2011 Financial Results on Wednesday, October 19, 2011
9/29/2011	Cubist Pharmaceuticals to Move CDAD Candidate into Phase 3
9/15/2011	Cubist Antibiotic Programs Featured in 49 Presentations at 51st ICAAC
8/29/2011	Cubist Pharmaceuticals to Present at September 2011 Investor Conferences
8/15/2011	Cubist Pharmaceuticals and the New England Patriots Radio Network Continue Program to Recognize Innovative Science Teachers
8/01/2011	Cubist Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Urinary Tract Infections
7/26/2011	Cubist Pharmaceuticals to Present at August 2011 Investor Conferences
7/14/2011	Cubist Pharmaceuticals 2Q11 Total Net Revenues $176.8 Million
7/14/2011	Cubist Pharmaceuticals 2Q11 Total Net Revenues $176.8 Million
6/27/2011	Cubist Pharmaceuticals Appoints Charles Laranjeira as Senior Vice President, Technical Operations
6/16/2011	Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
6/16/2011	Cubist Announces Positive Results from Two Phase 2 Trials, CXA-201 and CDAD Program
5/31/2011	Cubist Pharmaceuticals to Present at June 2011 Investor Conferences
5/03/2011	Cubist Pharmaceuticals to Present at May Investor Conference
5/02/2011	Cubist Pharmaceuticals’ Antibiotic Programs Featured in 18 Abstracts at 21st ECCMID/27th ICC Joint Congress

More Press Releases...

Source: SNL Financial LC


Copyright 2012, © SNL Financial LC Terms of Use